Emily Adams is Senior Lecturer in Diagnostics for Infectious Disease and Diagnostics Lead for LSTM’s Research Centre for Drugs and Diagnostics.
Emily’s research ranges from point-of-care diagnostics such as rapid-diagnostic-tests (RDTs) to simplified molecular diagnostics that can be used at the community level.
Emily’s team has been at the forefront of the development and validation of rapid diagnostic tests for COVID-19, including a partnership with Mologic on an antibody test which was developed for manufacture in the UK and in Dakar, Senegal. This work was critical in accelerating testing solutions for low- resource settings where diagnostic testing capacity is extremely low, but where rapid testing is essential in helping to contain transmission. Her work has also included understanding modes and of COVID-19 transmission in various settings. Emily is also part of a team leading a study measuring transmission and the impact of COVID-19 on households in Liverpool.
Emily’s other work includes diagnostics for emerging and parasitic infections, and anti-microbial resistance. She is a consultant for FIND, the Foundation for Innovation New Diagnostics, and has advised the World Health Organization and the Bill and Melinda Gates Foundation.